David Schilansky, CFO at DBV
Technologies SA, said, 'we are excited about being more visible in the US and having direct access to US investors through our NASDAQ listing.
Pierre-Henri Benhamou, chairman and chief executive officer of DBV
Technologies, said, "We are pleased to partner with Stallergenes on this exciting respiratory development program using a recombinant Birch allergen protein.
Pierre-Henri Benhamou, Chairman and CEO of DBV
Technologies, said: "The strategic manufacturing agreement with Sanofi is an important step for DBV
in the light of Viaskin's late-stage development and potentially fast-coming commercialization.
17 December 2010 - Danish immunotherapy company ALK-Abello A/S (CPH: ALK B) said today it will invest a further EUR2m in French biotech company DBV
Technologies to support the development of its peanut allergy vaccine.
Technologies Chief Business Officer Susanna Mesa, while speaking today at the Barclays Global Healthcare Conference, said the FDA will recognize the company as a pioneer in the field of food allergy treatment when reviewing its Biologics License Application for Viaskin Peanut.
Technologies SA (EPA: DBV
) has completed patient enrolment for its REALISE (REAL Life Use and Safety of EPIT) trial, the company revealed on Friday.
Allergy Therapeutics have also just come on board to sponsor the show alongside DBV
Technologies, Indoor Biotechnologies and Inflamax Research.
disclosed associations with Novartis, PepsiCo International, and DBV
) (Euronext: DBV
- ISIN: FR0010417345), creator of Viaskin[R], a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013.
Wainwright analyst Andrew Fein spent time with "leading" key opinion leaders in food allergy at this year's American Academy of Allergy, Asthma and Immunology meeting to talk about the oral immunotherapy from Aimmune Therapeutics (AIMT) and epicutaneous immunotherapy from DBV
Melincoff has experience serving on a board, having been a board member/board observer at Tobira Therapeutics (acquired by Allergan (NYSE: AGN)), DBV
Technologies (EPA: DBV
), AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc.
Speakers will include HAL Allergy, Stallergenes, Nestle, UCL, Allergy Therapeutics, DBV
Technologies, Danone, Chiesi, and more.